Prescription Drug News and Research RSS Feed - Prescription Drug News and Research

First Edition: April 16, 2014

Today's headlines include a report detailing how changes in the Census Bureau's annual survey could mask the health law's impact. [More]

Rite Aid's fourth quarter revenues increase 2.2% to $6.6 billion

Rite Aid Corporation today reported operating results for its fourth quarter and fiscal year ended March 1, 2014. [More]
TSRI scientists to study effects of pain medication on prenatal brain development

TSRI scientists to study effects of pain medication on prenatal brain development

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded a $472,500 Cutting Edge Basic Research Award (CEBRA) by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health to study models of the brain development of newborns who have been exposed-and become addicted-to prescription pain medication while still in the womb. [More]
Gilead Sciences announces positive results from LDV/SOF phase 2 studies on HCV infection

Gilead Sciences announces positive results from LDV/SOF phase 2 studies on HCV infection

Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from two Phase 2 studies evaluating investigational all-oral regimens containing the nucleotide analog polymerase inhibitor sofosbuvir (SOF) for the treatment of chronic hepatitis C virus (HCV) infection. [More]

2014 PAINWeekEnd Regional Conference to highlight health crises of inadequate pain management

There are 116 million people in pain. There are 4,000 pain specialists. That's 29,000 patients per pain specialist. There are simply not enough pain specialists to go around. [More]
FDA grants Fast Track designations for IV and oral formulations of Tetraphase's eravacycline

FDA grants Fast Track designations for IV and oral formulations of Tetraphase's eravacycline

Tetraphase Pharmaceuticals, Inc. today announced that the U.S. Food & Drug Administration has granted Fast Track designations for both the intravenous (IV) and oral formulations of the company's lead antibiotic candidate, eravacycline. [More]
BioAlliance Pharma, Daewoong sign new licensing agreement for commercialization of Sitavig in South Korea

BioAlliance Pharma, Daewoong sign new licensing agreement for commercialization of Sitavig in South Korea

BioAlliance Pharma SA, an innovative Company specialized in the development of drugs in orphan oncology diseases, today announces an exclusive supply and license agreement for Sitavig® (Acyclovir Lauriad®) with Daewoong Pharmaceutical Co., Ltd. for commercialization rights in South Korea. [More]
Study shows important parallels between epidemic of HIV/AIDS and opioid addiction

Study shows important parallels between epidemic of HIV/AIDS and opioid addiction

​There are important parallels between the early years of the HIV/AIDS epidemic and the current epidemic of opioid addiction - ones that could trigger a significant shift in opioid addiction prevention, diagnosis and treatment. [More]
FDA grants orphan drug designation to ERYTECH’s lead product for AML treatment

FDA grants orphan drug designation to ERYTECH’s lead product for AML treatment

ERYTECH Pharma, a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces that its lead product GRASPA®/ERY-ASP has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML), an aggressive form of blood cancer. [More]
FDA grants orphan drug designation for Kite Pharma's cancer immunotherapy product

FDA grants orphan drug designation for Kite Pharma's cancer immunotherapy product

Kite Pharma, Inc., a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, today announced that the U.S. Food and Drug Administration Office of Orphan Products Development granted orphan drug designation for the Company's lead investigational therapy, an autologous engineered T cell product that targets CD19 expression on B cell malignancies, for the treatment of diffuse large B cell lymphoma (DLBCL). [More]
Research roundup: Distance from a transplant center; Medicaid prenatal care; metastasis of email; profiting from Medicare Advantage

Research roundup: Distance from a transplant center; Medicaid prenatal care; metastasis of email; profiting from Medicare Advantage

Centralization of specialized health care services such as organ transplantation and bariatric surgery is advocated to improve quality, increase efficiency, and reduce cost. [More]
Roundup: Texas Medicaid fraud settlement; Texas abortion law upheld; Va. mental health tragedy details

Roundup: Texas Medicaid fraud settlement; Texas abortion law upheld; Va. mental health tragedy details

A selection of health policy stories from Texas, Virginia, California, Michigan and Massachusetts. [More]

FDA accepts AVP-825 NDA for acute treatment of migraine

The U.S. Food and Drug Administration has accepted the New Drug Application (NDA) for AVP-825, an innovative closed-palate Breath Powered investigational drug-device combination product for the acute treatment of migraine. [More]

pSivida resubmits New Drug Application for ILUVIEN

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the U.S. Food and Drug Administration (FDA). [More]

Biodelivery Sciences collaborates with Quintiles to launch BUNAVAIL in the U.S.

BioDelivery Sciences International, Inc. announced that it has entered into an agreement with Quintiles to provide a range of services to support the anticipated launch of BUNAVAIL (buprenorphine and naloxone buccal film), BDSI's proposed maintenance treatment for opioid dependence. [More]

Alimera Sciences resubmits New Drug Application for ILUVIEN

Alimera Sciences, Inc. (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has resubmitted its New Drug Application for ILUVIEN® to the U.S. Food and Drug Administration (FDA). [More]
Quarter of breast cancer survivors are worse off financially due to treatment

Quarter of breast cancer survivors are worse off financially due to treatment

Four years after being treated for breast cancer, a quarter of survivors say they are worse off financially, at least partly because of their treatment, according to a new study led by University of Michigan Comprehensive Cancer Center researchers. [More]
Treat or eat: Many people forced to choose between food or medicine

Treat or eat: Many people forced to choose between food or medicine

Chronically ill adults who reported food insecurity in their household (not having consistent access to food due to lack of financial stability) were significantly more likely to report cost-related medication underuse, according to a new study in The American Journal of Medicine,. The term cost-related medication underuse refers to taking less medication than prescribed, or not taking it at all due to financial concerns. [More]
Research roundup: Medicaid eligibility; tracking discontinued randomized trials; decline in work-based insurance

Research roundup: Medicaid eligibility; tracking discontinued randomized trials; decline in work-based insurance

Under the Affordable Care Act (ACA), changes in income and family circumstances are likely to produce frequent transitions in eligibility for Medicaid and health insurance Marketplace coverage for low- and middle-income adults. [More]

Transamerica obtains 4-star Medicare Part D rating from CMS for 2014

Transamerica continues to provide exceptional value to Medicare customers by obtaining a 4-star Medicare Part D rating from the Centers for Medicare and Medicaid Services for 2014. [More]